Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials

Chan JCN 1 , Bunnag P 2 , Chan SP 3 , Tan ITI 4 , Tsai ST 5 , Gao L 6 Show all authors , Landgraf W 7

Affiliations 

  • 1 Department of Medicine and Therapeutics, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong. Electronic address: [email protected]
  • 2 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 3 University of Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 4 University of The Philippines, Manila, Philippines
  • 5 Cheng Hsin General Hospital, Taipei, Taiwan
  • 6 Analysta Inc., Somerset, NJ, USA
  • 7 Sanofi, Frankfurt, Germany
Diabetes Res Clin Pract, 2018 Jan;135:199-205.
PMID: 29179974 DOI: 10.1016/j.diabres.2017.11.025

Abstract

AIMS: To compare outcomes between Asian and non-Asian patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs (OADs) initiating insulin glargine 100 units (U)/mL (Gla-100) in randomised controlled clinical trials.

METHODS: Post hoc analysis of patient-level data (Asian n = 235; non-Asian n = 3351) from 16 trials.

RESULTS: At baseline, Asian patients were younger with lower body mass index (BMI), fasting C-peptide, and fasting plasma glucose (FPG) than non-Asian patients (all P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications